Cardiorenal risk of celecoxib compared with naproxen or ibuprofen in arthritis patients: insights from the PRECISION trial.
Slayman ObeidPeter LibbyElaine HusniQiuqing WangLisa M WisniewskiDeborah A DaveyKatherine E WolskiFeng XiaWeihang BaoChris WalkerFrank RuschitzkaSteven E NissenThomas Felix LüscherPublished in: European heart journal. Cardiovascular pharmacotherapy (2022)
In the current era, long-term NSAID use was associated with few cardiorenal events in arthritis patients. At the doses studied, celecoxib displayed fewer renal events and hence more favourable cardiovascular safety compared with ibuprofen or naproxen. These results have considerable clinical implications for practitioners managing individuals with chronic arthritis pain and high risk of impaired renal function and/or heart failure.Clinical Trial Registration: NCT00346216.
Keyphrases
- clinical trial
- rheumatoid arthritis
- heart failure
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- study protocol
- primary care
- phase ii
- chronic pain
- phase iii
- randomized controlled trial
- prognostic factors
- neuropathic pain
- postoperative pain
- pain management
- patient reported outcomes
- spinal cord injury
- general practice
- spinal cord
- drug induced
- acute heart failure
- placebo controlled